An Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious Puberty
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Triptorelin (Primary)
- Indications Precocious puberty
- Focus Registrational; Therapeutic Use
- Sponsors Debiopharm
- 19 May 2015 Results published in Debiopharma media release.
- 13 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Aug 2012 The first patient has been enrolled into this trial, according to a Debiopharm media release.